|
Active substance |
Pertuzumab |
|
Holder |
Roche |
|
Status |
Closed |
|
Indication |
in combination with Herceptin® (trastuzumab) and chemotherapy for the adjuvant treatment of adult patients with HER2 positive early breast cancer at high risk of recurrence defined as lymph node positive disease |
|
Public documents |
|
|
Last update |
09/07/2019 |
Perjeta®
Last updated on 13/09/2024